Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Can-Fite BioPharma ( (CANF) ) has shared an announcement.
On May 5, 2025, Can-Fite BioPharma announced it has raised $175 million to advance its lead drug candidates, Namodenoson and Piclidenoson, into pivotal Phase III trials for liver cancer and psoriasis. This funding milestone supports the company’s strategic clinical developments and strengthens its market position, with both drugs showing promising efficacy and safety profiles. Additionally, Can-Fite has secured seven commercialization agreements for future marketing and continues to seek further partnerships.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
Can-Fite BioPharma’s overall stock score of 40 reflects significant financial weaknesses, including declining revenues, persistent losses, and negative cash flow. The technical analysis supports a bearish outlook with negative momentum indicators. Furthermore, valuation is unattractive due to a negative P/E ratio and lack of dividend yield. Improvement in operational efficiency and financial stability are critical for future performance.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company specializing in the development of small-molecule drugs targeting oncological and inflammatory diseases. The company focuses on therapies that target the A3 adenosine receptor, which is prevalent in inflammatory and cancer cells. Its lead drug candidates, Namodenoson and Piclidenoson, are being developed for liver cancer and psoriasis, respectively. Can-Fite is also exploring treatments for pancreatic cancer and metabolic dysfunction-associated steatohepatitis (MASH).
YTD Price Performance: -37.15%
Average Trading Volume: 300,745
Technical Sentiment Signal: Buy
Current Market Cap: $16.28M
For a thorough assessment of CANF stock, go to TipRanks’ Stock Analysis page.